Tumor thickness at the tumor-normal interface: A novel pathologic indicator of chemotherapy response in hepatic colorectal metastases

American Journal of Surgical Pathology

Volumn 34, Issue 9, 2010, Pages 1287-1294

  Maru, Dipen M ^a   Kopetz, Scott ^a   Boonsirikamchai, Piyaporn ^a   Agarwal, Atin ^a   Chun, Yun Shin ^a   Wang, Huamin ^a   Abdalla, Eddie K ^a   Kaur, Harmeet ^a   Charnsangavej, Chusilp ^a   Vauthey, Jean Nicolas ^a   Loyer, Evelyne M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

colon cancer; liver metastases; pathology response; radiologic response; tumor thickness

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES;

EID: 77956225027     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181eb2f7b     Document Type: Article

References (20)

1. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-1641.
2. American Joint Committee on Cancer Staging Atlas. 7th ed. New York, NY: Springer, 2010, 77-89.
3. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-5351.
4. Cao Y, Tan A, Gao F, et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009;24:677-685.
5. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response, after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72:99-107.
6. Charnsangavej C, Clary B, Fong Y, et al. Expanding criteria for resection of hepatic colorectal metastases; expert consensus statement. Ann Surg Oncol. 2006;3910:1261-1268.
7. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338-2344.
8. Ellis LM. Mechanism of action of bevasizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33(5 suppl 10):S1-S7.
9. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004;4: 806-813.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
11. Jaeck D, Pessaux P. Bilobar colorectal liver metastases: treatment options. Surg Oncol Clin N Am. 2008;17:553-568.
12. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-3712.
13. Kokudo N, Imamura H, Sugawara Y, et al. Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg. 2004;11:84-91.
14. Kopetz S, Chang G, Overman M, et al. Improved survival in meta-static colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
15. Mentha G, Terraz S, Morel P, et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg. 2009;96:95-103.
16. Ribero D, Wang H, Donaton M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761-2767.
17. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18: 299-304.
18. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75-81.
19. Ryan R, Gibbons D, Hyland JPM, et al. Pathological response following long course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47:141-146.
20. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.